TEKY yields 0.28% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, TEKY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TEKY + JNJ for your $10,000?
TEKY invests globally in companies at the forefront in developing or enabling next-generation technologies, particularly artificial intelligence (AI). The fund targets approximately 40 to 60 companies across three segments: hardware infrastructure, enabling technologies, and AI application vendors. A proprietary data science platform is used to screen and rank potential securities based on their business exposure to AI, considering factors like product offerings, intellectual property, R&D efforts, revenue, and market presence. From this universe, a bottom-up stock selection process is employed, using tailored valuations approaches, revenue-based for early-stage firms and EV/EBITDA for established businesses. Investments include common and preferred stocks, ADRs, GDRs, warrants, rights, and participatory notes. Additionally, it may use futures and swaps for hedging or enhancing returns. The fund may hedge foreign currency exposure through forward contracts, depending on market conditions.
Full TEKY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.